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Background: Calprotectin is a marker of inflammation, but its clinical utility in dogs with chronic
inflammatory enteropathies (CIE) is unknown.
Objective: Evaluation of fecal calprotectin in dogs with biopsy-confirmed CIE.
Animals: 127 dogs.
Methods: Prospective case-control study. Dogs were assigned a canine chronic enteropathy clini-
cal activity index (CCECAI) score, and histologic lesions severity was assessed. Fecal calprotectin,
fecal S100A12, and serum C-reactive protein (CRP) were measured. Food- or antibiotic-responsive
cases (FRE/ARE, n513) were distinguished from steroid-/immunosuppressant-responsive or
-refractory cases (SRE/IRE, n520). Clinical response to treatment in SRE/IRE dogs was classified
as complete remission (CR), partial response (PR), or no response (NR).
Results: Fecal calprotectin correlated with CCECAI (q50.27, P5 .0065) and fecal S100A12
(q50.90, P< .0001), some inflammatory criteria, and cumulative inflammation scores, but not
Abbreviations: ARE, antibiotic-responsive enteropathy; AUROC, area under the ROC curve; CCECAI, canine chronic enteropathy clinical activity index; DCCECAI,
change in CCECAI; CD, Crohn’s disease; CI, confidence interval; CIBDAI, canine IBD activity index; CIE, chronic inflammatory enteropathy; CR, complete
remission; CRP, C-reactive protein; FRE, food-responsive enteropathy; GI, gastrointestinal; IBD, inflammatory bowel disease; IQR, interquartile range; IRE,
immunosuppressant-responsive/-refractory enteropathy; MU, macrophage(s); NF-jB, nuclear factor-kappa B; NR, no response; OR, odds ratio; PR, partial
response; ROC, receiver operating characteristic; SRE, steroid-responsive/-refractory enteropathy; TAMU, Texas A&M University; TLR, Toll-like receptor; UC,
ulcerative colitis.
Dogs were enrolled in the study and the samples collected at the Gastrointestinal Laboratory at Texas A&M University, the College of Veterinary Medicine at
Purdue University, or at one of several other referral hospitals across the United States. Sample analyses were performed at Texas A&M University and Purdue
University. Data analysis and manuscript writing were done at the College of Veterinary Medicine at the University of Leipzig.
Part of these data were presented as a research report at the 2017 American College of Veterinary Internal Medicine Forum, National Harbor, MD.
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serum CRP (q50.16, P5 .12). Dogs with SRE/IRE had higher fecal calprotectin concentrations
(median: 2.0 lg/g) than FRE/ARE dogs (median: 1.4 lg/g), and within the SRE/IRE group,
dogs with PR/NR had higher fecal calprotectin (median: 37.0 lg/g) than dogs with CR (median: 1.6
lg/g). However, both differences did not reach statistical significance (both P5 .10). A fecal calpro-
tectin 15.2 lg/g separated both groups with 80% sensitivity (95% confidence interval [95%CI]:
28%-100%) and 75% specificity (95%CI: 43%-95%).
Conclusions and Clinical Importance: Fecal calprotectin could be a useful surrogate marker of
disease severity in dogs with CIE, but larger longitudinal studies are needed to evaluate its utility in
predicting the response to treatment.
K E YWORD S
antibiotic-responsive enteropathy, biomarker, calgranulin, canine, food-responsive enteropathy,
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1 | INTRODUCTION
Chronic inflammatory enteropathies (CIE) comprise an important group
of disorders in dogs1,2 that are characterized by chronic persistent or
recurrent gastrointestinal (GI) signs and histopathologic evidence of pri-
mary intestinal mucosal inflammation.1,3,4 Based on the response to
treatment, canine non-infectious CIE are classified as food-responsive
enteropathy (FRE), antibiotic-responsive enteropathy (ARE), or steroid-/
immunosuppressant-responsive (or -refractory) enteropathy (SRE/
IRE).1,2
A diagnosis of canine SRE/IRE can be challenging as it involves a
comprehensive diagnostic investigation to exclude other causes of
chronic GI signs (eg, hypoadrenocorticism, exocrine pancreatic insuffi-
ciency, endoparasites), to document mucosal inflammation based on
histopathology, to demonstrate an inadequate clinical response to
appropriately designed dietary and antibiotic treatment trials, and to
show clinical improvement with anti-inflammatory/immunosuppressive
therapy (or lack thereof in refractory cases).1–4 The pathogenesis of
canine SRE/IRE is poorly understood, and an impaired immunoregula-
tion and overt inflammatory response against dietary and bacterial anti-
gens appears to play a central role, together with the presence of a
genetic predisposition.3,5
Recent advances in the diagnosis of CIE include the development of
a 6-parameter6 (considering the dog’s attitude/activity, appetite, vomit-
ing, feces consistency, feces frequency, and weight loss; the cumulative
score can range from 0 to 18) and a 9-parameter clinical scoring system7
(which considers the dog’s attitude/activity, appetite, vomiting, feces
consistency, feces frequency, weight loss, serum albumin concentration,
ascites/peripheral edema, and pruritus; the cumulative score can range
from 0 to 27), an endoscopic lesion score,8 and a consensus for classify-
ing CIE based on histopathologic criteria.3,9 However, only a few mini-
mally or noninvasive biomarkers of inflammation have been evaluated in
dogs with CIE,10–18 none of which are currently routinely used in clinical
practice.
Canine calprotectin, the S100A8/A9 protein complex, and also
S100A12 are Ca21-binding proteins of the S100/calgranulin family that
have been shown to be associated with acute and chronic inflammation
and with malignant transformation.5 These proteins are involved in the
regulation of cell proliferation and metastasis, and after their extracellular
release function as endogenous danger-signaling molecules (alarmins).19
Calprotectin and S100A12 have potential as markers of inflammation in
dogs.11,15,16,19–21 In canine CIE, the expression of mucosal S100-mRNA
was shown to be increased 11-fold.22 Fecal calprotectin and S100A12
have been shown to be correlated with the clinical disease activity,15,20,21
and the latter also correlated with the severity of endoscopic lesions15
and the response to treatment in dogs with CIE.16
C-reactive protein (CRP) is a positive acute-phase protein of the
pentraxin family that is produced by the liver in response to IL-6 and
IL-1b during states of infection, inflammation, or cancer.23 Serum CRP
concentration has been suggested to serve as a marker of disease pro-
gression and response to treatment in dogs with SRE/IRE.6,10,11
We hypothesized that fecal calprotectin concentrations (1) are
associated with the severity of clinical signs, histologic lesions, or both
(2) predict the response to different forms of treatment, and (3) corre-
late with the concentration of other biomarkers of intestinal inflamma-
tion. To prove or disprove these hypotheses, the objectives of our
study were to evaluate fecal calprotectin concentrations in dogs with
CIE in relation to (1) the severity of clinical signs and histologic lesions,
(2) disease classification (SRE/IRE versus FRE/ARE) and response to
treatment (complete remission [CR] versus partial or no response [NR]),
and (3) the concentration of serum CRP and fecal S100A12. In addition,
the possibility of an association between fecal calprotectin and the
concentration of calprotectin and S100A12 in serum was tested.
2 | MATERIALS AND METHODS
2.1 | Ethics approval
The study design was reviewed and approved by the Clinical Research
Review Committee (CRRC# 2009-06 and 2010-05) and the Institu-
tional Animal Care and Use Committee (IACUC, AUP# 2012-083) at
Texas A&M University (TAMU). The owner of each enrolled dog had to
give written consent to the study before the inclusion of the dog.
Based on our preliminary data,24 a sample size of at least 20 dogs per
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group was calculated to be required to reveal a difference in fecal
canine calprotectin concentrations of at least 20 lg/g with a statistical
power of >80% (a50.05, b50.2; enrollment ratio51:1).25
2.2 | Sampling population
Dogs (n5225) >6 months of age presenting for routine diagnostic
evaluation of chronic (2–3 weeks duration) signs of GI disease (ie,
vomiting, diarrhea, hypo- or anorexia, abdominal pain, weight loss),
including a planned endoscopic or surgical collection of GI tissue biop-
sies, were prospectively enrolled in the study between August 2009
and July 2015 (Figure 1) at the Veterinary Teaching Hospitals at TAMU
or Purdue University, or at 1 of several other referral hospitals across
the United States. All dogs underwent a routine diagnostic evaluation
according to current guidelines,3 which included a CBC, serum
chemistry profile, urinalysis, and additional diagnostics to rule out other
causes of chronic signs of GI disease (eg, endoparasites based on a
fecal examination, hypoadrenocorticism based on a serum baseline cor-
tisol measurement, and an adrenocorticotropic hormone stimulation
test if indicated). The severity of the dog’s clinical signs at presentation
was assessed by the attending clinician using the 9-variable canine
chronic enteropathy clinical activity index (CCECAI) scoring system,
and a CCECAI of 1 (ie, minimal to mild clinical disease severity) was
required for inclusion in the study.7 A study questionnaire evaluating
the dog’s overall health, diet, and medication history also had to be
completed by the owner. Treatment of each individual dog, including
dietary management, antibiotic treatment, and supplements (including
prebiotics and probiotics), anti-inflammatory or immunosuppressant
therapy, or all was at the discretion of the attending clinician. Sequen-
tial treatment trials (elimination diet for a minimum of 2–3 weeks each,
FIGURE 1 Study flow chart. Flow diagram summarizing the group distribution of the 225 dogs considered for inclusion in the study. The 3
different parts of the study (gray shaded areas) were: evaluation of (I) fecal calprotectin in relation to clinical disease severity (CCECAI
score); (II) fecal calprotectin and microscopic lesion severity (histologic lesion score); and (III) fecal calprotectin in relation to disease
classification and response to treatment. GI, gastrointestinal; #not recorded from 1 dog; aCCECAI score 5; bCCECAI score 6–8; cCCECAI
score 9–11; dCCECAI score 12
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antibiotic trial for at least 10–14 days) were required to be performed
to further characterize the disease process,1,3 with a deviation from this
scheme being allowed for dogs with very severe clinical signs or marked
abnormal clinicopathologic findings (ie, hypoalbuminemia or panhypopro-
teinemia).3,7 The time point of GI tissue specimen collection was also at
the clinician’s discretion. Dogs were only included in the study if they
had not received any anti-inflammatory/immunosuppressive treatment
during the 2 weeks before enrollment and initial sample collection.
Exclusion criteria for the study that were applied retrospectively,
were the lack of intestinal biopsies submitted from a dog or if intestinal
biopsies submitted were of inadequate quality (n590). Further, dogs
were excluded if neoplasia was identified on GI histopathology (n58).
Follow-up information was available from some dogs (n532)
using the same study questionnaire including a CCECAI scoring sheet,
and was used to characterize the disease (ARE: clinical response to
tylosin or metronidazole defined as a CCECAI50 or a percentage of
change in the CCECAI score [DCCECAI] >75% at the time of recheck;
FRE: clinical response to an easily digestible diet, a novel protein diet,
or a diet containing hydrolyzed protein with CCECAI50 or DCCECAI
>75% at the time of recheck; SRE/IRE: requiring treatment with anti-
inflammatory drug, immunosuppressive drugs, or both).1,2 Five dogs
that did not have biopsies collected and were categorized as either
FRE or ARE based on complete follow-up information (follow-up time
6–169 weeks) were included in the group comparison (Figure 1). Fur-
ther, the response to treatment in 17 dogs with SRE/IRE was deter-
mined based on the DCCECAI as either CR (DCCECAI >75% or clinical
signs resolved [ie, CCECAI50]), partial response (PR; DCCECAI 25%-
75% or clinical signs improved), or NR (DCCECAI <25% or clinical signs
same or worse).10,16
2.3 | Sample collection
Single whole blood (ethylenediaminetetraacetic acid was used as anti-
coagulant), serum, and urine specimens were collected from each dog
at the first presentation for diagnostic work-up and, if a reevaluation
was performed according to the study protocol, at the respective
recheck(s). Whole blood and serum were collected after food was with-
held for at least 12 hours. Fecal samples (an aliquot of approximately
1 g each) were collected from 3 consecutive days.26 Endoscopic
(n5113) or surgical (n514) GI tissue biopsies were obtained from
each dog (Figure 1) with the method of tissue collection being left at
the discretion of the attending clinician. Within 1 day of collection, all
specimens, including GI tissues (if obtained as part of the diagnostic
work-up), collected outside of TAMU were shipped to the Gastrointes-
tinal Laboratory at TAMU overnight on ice packs.
Follow-up data were included from dogs that were clinically
reevaluated as described and sample sets were collected at the time of
recheck evaluation.
2.4 | Sample analyses
Whole blood was used for routine hematology (performed at the insti-
tution recruiting the case for the study or the Texas Veterinary Medical
Diagnostic Laboratory). Serum was used for a blood chemistry profile
(LiquiColor, Sirrus clinical chemistry analyzer, Stanbio Laboratory,
Boerne, Texas), and for measurement of serum cobalamin (Immulite
2000, Vitamin B12, Siemens Healthcare Diagnostics Inc., Deerfield,
Illinois), folate (Immulite 2000, Folic Acid, Siemens Healthcare Diagnos-
tics Inc.), and CRP (Tri-Delta Phase CRP, Tri-Delta Diagnostic, Boonton
Township, New Jersey)27 concentrations. Urine samples were used for
routine urinalysis (performed at the institution recruiting the respective
case for the study or the TAMU Clinical Pathology service) and,
if indicated, further diagnostic testing (ie, urine culture, urine
protein/creatinine ratio).
Fecal and serum calprotectin concentrations were measured using
a species-specific sandwich ELISA.26 The working range of the assay for
serum is 0.3–26.8 mg/L and is 3.2–267.6 lg/g for fecal extracts. The
assay was demonstrated to not cross-react with the canine S100A12
protein.26 Intra- and inter-assay coefficients of variation (%CV) of the
assay are 12.7% and 17.2% for serum samples and 10.0% and
12.3% for fecal extracts.26 The 3-day mean fecal calprotectin concen-
tration was calculated26 and used for statistical analyses. Fecal and
serum S100A12 concentrations were measured by a species-specific
in-house sandwich ELISA,28 and the 3-day mean fecal S100A12 con-
centration was also calculated and used for analyses.
2.5 | Histopathologic evaluation of gastrointestinal
tissue biopsies
Histopathologic evaluation of GI tissue biopsies was performed by 1 of
7 board-certified pathologists (Gastrointestinal Histopathology service,
Gastrointestinal Laboratory at Texas A&M University, College Station,
Texas; median of 14 dogs evaluated by each pathologist, range: 1–34)
using the World Small Animal Veterinary Association Gastrointestinal
Standardization grading system.3 The severity of morphologic lesions
and inflammatory changes in the duodenum, ileum, and colon were
recorded using a 4-point grading system (05normal, 15mild lesions,
25moderate lesions, and 35 severe lesions). Individual and cumula-
tive lesion scores (calculated as the sum of individual lesion scores)
were considered for statistical analyses. Gastric biopsies were eval-
uated to rule out evidence of neoplastic disease, but inflammatory
changes were not graded.
2.6 | Data analyses
Statistical software packages were used for all statistical analyses (JMP
v13.0, SAS Institute, Cary, North Carolina, GraphPad Prism v7.0,
GraphPad Software, San Diego, California). Continuous variable data
were first assessed for normality of their distribution and equality of
the variances using a Shapiro-Wilk W test and a Brown-Forsythe test,
respectively. Summary statistics for continuous variables are reported
as medians and interquartile ranges (IQR). Categorical data are pre-
sented as counts (n) and percentages.
A non-parametric Wilcoxon rank-sum test was utilized to compare
continuous variables between dogs with SRE/IRE and the group of
dogs with FRE/ARE, and also in SRE/IRE dogs with CR versus PR/NR.
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A likelihood ratio test or a Fisher’s exact test (as appropriate) was used
to test the association between categorical variables and disease group
or response to treatment. A non-parametric Spearman rank correlation
coefficient q was calculated to test for any possible correlation
between fecal calprotectin concentrations and the CCECAI scores, indi-
vidual and cumulative histologic lesion scores, and the concentrations
of serum CRP, fecal and serum S100A12, and serum calprotectin. The
Spearman q was interpreted as indicating a very strong (0.8–1.0),
strong (0.6–0.8), moderate (0.4–0.6), weak (0.2–0.4), or very weak
(0–0.2) correlation. A Wilcoxon signed rank test served to compare
fecal calprotectin concentrations before and after treatment. Statistical
significance was set at P< .05, and a Bonferroni correction for multiple
statistical comparisons (Pcorr5 P 4 n) at the same level was applied, if
indicated.
A receiver operating characteristic (ROC) curve analysis served to
calculate the sensitivity and specificity at optimum cut-off concentra-
tions (determined by the Youden index) to differentiate (1) dogs with
SRE/IRE from those dogs with FRE/ARE and (2) SRE/IRE dogs with
PR/NR from those dogs with CR. A Fisher’s exact test, with calculation
of the odds ratio (OR) and 95% confidence interval (95%CI), served to
test the possibility and the odds of an association between a fecal cal-
protectin concentration of 15.2 lg/g, a serum CRP concentration of
9.1 mg/L (or 12.9 mg/L), a CCECAI score 8 (or 12), or different
combinations of these and (1) a diagnosis of SRE/IRE versus FRE/ARE
and (2) a PR/NR versus CR in dogs with SRE/IRE. The probabilistic
solution was used to estimate the OR with zero values.29
3 | RESULTS
3.1 | Study population
A total of 127 dogs diagnosed with CIE (median age: 7 years, IQR: 4–9
years; 64 males/63 females) were included in the study (Figure 1,
Table 1). Median CCECAI score was 7 (moderate disease; IQR: 5–10)
and median histologic lesion score was 2 (moderate lesions; IQR: 1–3)
(Figure 1, Table 1). Median serum cobalamin and folate concentrations
were 326 ng/L and 12.9 lg/L, respectively. Hypocobalaminemia (serum
cobalamin concentration 250 ng/L30) was detected in 38 dogs (30%),
of which 16 dogs (13%) had an undetectable serum cobalamin concen-
tration (149 ng/L). Hypofolatemia (serum folate concentration
7.7 lg/L31) was seen in 17 dogs (14%), and hyperfolatemia (serum
folate concentration 24.4 lg/L31) in 6 dogs (5%). Breeds most com-
monly represented in our study included German Shepherd dogs
(n510), Yorkshire terriers (n59), and mixed breed dogs (n522).
Of the 32 dogs with CIE from which follow-up information was
available, 19 dogs were diagnosed with SRE/IRE and 13 dogs with FRE
or ARE (Figure 1, Table 1). In the FRE group, an easily digestible diet
was given to 2 dogs, a novel protein diet to 2 dogs, and a diet contain-
ing hydrolyzed protein to 4 dogs; 1 FRE dogs was given a home-
prepared limited antigen diet. In the SRE/IRE group, dogs received
prednisone/prednisolone (n515) or budesonide (n54), azathioprine
(n54), or cyclosporine (n51); 5 of the dogs received a combination of
2 medications. Dietary choices in SRE/IRE dogs were an easily
digestible or low-fat diet (n53), a novel protein diet (n54), and a diet
containing hydrolyzed protein (n59); 3 SRE/IRE dogs were given a
home-prepared limited antigen diet.
Total (ie, maximum) follow-up time ranged from 2 to 169 weeks
(median: 8 weeks, IQR: 4–13 weeks), with a first follow-up at a median
of 5 weeks (IQR: 3–9 weeks). A first follow-up with recollection of
samples (serum and feces) and data exactly 3–4 weeks after the initial
work-up (ie, collection of biopsies) was only accomplished in 14 of the
32 dogs (44%). About a third of the dogs (11/32) with a first set of
follow-up samples and data had at least 1 additional follow-up
recorded at a later time. The response to treatment was assessed retro-
spectively based on the longest available follow-up time.
Sex and age did not differ between dogs diagnosed with SRE/IRE
and dogs with FRE/ARE (Table 1). However, dogs with SRE/IRE had
significantly higher CCECAI scores (median: 9, IQR: 5–11) than dogs
with FRE/ARE (median: 5, IQR: 3–7; Pcorr50.018, Table 1). Sex and
CCECAI scores did not differ between SRE/IRE dogs with CR and
those dogs with PR/NR (P5 .59 and P5 .49, respectively), but dogs
with PR/NR were significantly older (median511 years, IQR57–12
years) than those dogs with CR (median58 years, IQR: 5–8 years;
P5 .039).
3.2 | Fecal calprotectin concentrations and other
biomarkers
Calprotectin concentrations ranged from 0.04 to 1,971.0 lg/g in indi-
vidual fecal samples from all 127 dogs, with the 3-day mean fecal cal-
protectin concentrations ranging from 0.04 to 992.5 lg/g (median: 1.6
lg/g, IQR: 0.5–15.3 lg/g). Serum CRP concentrations ranged from 0.1
to 81.0 mg/L (median: 1.6 mg/L, IQR: 0.1–11.4 mg/L) in all dogs with
CIE. Fecal S100A12 concentrations ranged from 1 to 101,980 ng/g in
individual fecal samples from all CIE dogs, with the 3-day mean fecal
S100A12 concentrations ranging from 1 to 41,660 ng/g (median: 65
ng/g, IQR: 14–425 ng/g).
Fecal calprotectin concentrations were correlated with fecal
S100A12 concentrations (q50.90, Pcorr< .0006), but showed no asso-
ciation with serum concentrations of CRP (q50.16, Pcorr5 .71), calpro-
tectin (q50.14, Pcorr51.00), or S100A12 (q50.09, Pcorr51.00)
(Table 2).
3.3 | Fecal calprotectin concentrations and clinical
disease severity
Three-day mean fecal calprotectin concentrations were weakly corre-
lated with the CCECAI score at the time of enrollment (q50.27,
Pcorr5 .039).
3.4 | Other biomarkers and clinical disease severity
Correlation with the CCECAI score was also seen for serum CRP con-
centrations (q50.42, Pcorr< .0006), but not for fecal S100A12 concen-
trations (q50.24, Pcorr5 .097).
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TABLE 1 Dog characteristics, clinical findings, and clinicopathologic parameters in dogs with chronic inflammatory enteropathies (CIE)
included in the study
Group characteristic CIE (all) FRE/AREa SRE/IRE P valueb Pcorr
c
Total number, n 127 13 19 – –
Dog characteristics
Age in years, median (IQR) 7 (4–9) 6 (3–9) 8 (7–10) .13 1.00
Sex, male/female 64/63 9/4 10/9 .34 1.00
Body weight in kg, median (IQR) 15.1 (6.6–26.2) 13.2 (5.3–26.7) 16.4 (4.7–25.0) .80 1.00
Breed, n (%) .79 1.00
- Pure-bred 105 (83%) 12 (92%) 17 (89%)
- Mixed breed 22 (17%) 1 (8%) 2 (11%)
Follow-up duration in weeks, median (IQR) – 13 (5–21) 8 (4–11) .08 .96
Response to treatment,d n (%) – –
- Complete remission (CR) – – 12 (70%)
- Partial response (PR) 3 (18%)
- No response (NR) 2 (12%)
Biopsy type, n (%)
- Endoscopic 113 (89%) 7 (54%) 18 (95%)
- Surgical 14 (11%) 1 (8%) 1 (5%) .53 1.00
Number of sites biopsied, median (IQR) 2 (2–3) 3 (2–4) 2 (2–3) .49 1.00
Number of biopsies per site, median (IQR)
- Stomach (not analyzed) 12 (8–15) 10 (7–15) 10 (9–19) .65 1.00
- Duodenum 12 (6–17) 9 (6–12) 12 (11–14) .11 1.00
- Ileum 4 (1–11) 1 (1–4) 6 (1–11) .35 1.00
- Colon 12 (8–17) 12 (10–17) 11 (6–17) .76 1.00
Histologic lesion score, median (IQR) 2 (1–3) 2 (1–2) 2 (1–2) .84 1.00
Clinical parameters
Disease duration in months, median (IQR) 6 (3–17) 4 (2–11) 3 (1–9) .52 1.00
Clinical signs, n (%)
- Vomiting 78 (61%) 8 (62%) 9 (47%) .43 1.00
- Diarrhea 96 (76%) 10 (77%) 15 (79%) .89 1.00
- Weight loss 78 (61%) 7 (54%) 9 (47%) .72 1.00
- Hypo- or anorexia 65 (51%) 2 (15%) 11 (58%) .013 .090
CCECAI score,e median (IQR) 7 (5–10) 5 (3–7) 9 (5–11) .0025 .018
Clinical disease severity,e n (%)
- Mild (CCECAI score5) 47 (37%) 7 (58%) 6 (31%) .026 .18
- Moderate (CCECAI score 6–8) 30 (24%) 4 (33%) 2 (11%)
- Severe (CCECAI score 9–11) 29 (23%) 1 (9%) 9 (47%)
- Very severe (CCECAI score12) 20 (16%) – 2 (11%)
Clinicopathologic parameters
Serum cobalamin in ng/L,f median (IQR) 326 (217–653) 439 (248–877) 301 (194–345) .14 1.00
Hypocobalaminemia,f,g n (%) 38 (30%) 3 (23%) 8 (42%) .33 1.00
Serum folate in lg/L,f median (IQR) 12.9 (9.5–16.6) 14.2 (9.7–21.4) 15.8 (11.3–19.5) 1.00 1.00
Hypofolatemia,f,h n (%) 17 (14%) 0 (0%) 3 (16%) .077 .54
Serum albumin in g/dL,i median (IQR) 3.0 (2.5–3.3) 3.2 (2.9–3.5) 2.3 (1.7–3.5) .0012 .0084
Hypoalbuminemia,i,j n (%) 50 (40%) 1 (8%) 9 (47%) .0082 .057
Hypoalbuminemia severity,i n (%)
- Minimal (albumin 2.0–2.4 g/dL) 15 (12%) 0 (0%) 2 (10.5%) .056 .39
- Mild (albumin 1.5–1.99 g/dL) 17 (14%) 0 (0%) 4 (21%)
(Continues)
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3.5 | Fecal calprotectin concentrations and
microscopic lesion severity
Fecal calprotectin concentrations were correlated with the number of
intraepithelial lymphocytes in the duodenum (q50.30, Pcorr5 .027)
and with the overall cumulative inflammatory lesion score (q50.52,
P5 .018; Table 2), whereas the correlation with the lamina propria lym-
phoplasmacytic infiltration (q50.41, Pcorr5 .14) and the overall inflam-
matory lesion score in the ileum (q50.38, Pcorr5 .08) did not remain
significant after correction for multiple comparisons.
3.6 | Other biomarkers and microscopic lesion
severity
Serum CRP concentrations were associated with the severity of mor-
phologic lesions in the duodenum (Table 2). However, there was no sig-
nificant correlation between serum CRP concentrations and the
severity of microscopic lesions in the ileum or colon; neither did serum
CRP concentrations correlate with the cumulative histologic lesion
scores (Table 2). Fecal S100A12 concentrations were significantly cor-
related with the number of duodenal lamina propria intraepithelial lym-
phocytes (q50.30, Pcorr5 .017), whereas the relationship with other
inflammatory criteria did not reach significance (Table 2).
3.7 | Fecal calprotectin concentrations and disease
classification
Fecal calprotectin concentrations were numerically higher in dogs diag-
nosed with SRE/IRE (median: 2.0 lg/g, IQR: 1.1–37.0 lg/g) compared
to dogs with FRE or ARE (median: 1.4 lg/g, IQR: 0.5–2.4 lg/g), but the
difference did not reach significance (P5 .10) (Figure 2). Using a cut-off
fecal calprotectin concentration of 15.2 lg/g yielded a sensitivity of
37% (95%CI: 18%–57%) and a specificity of 100% (95%CI: 70%–100%;
area under the ROC curve [AUROC]: 67%, 95%CI: 49%–86%) for the
diagnosis of SRE/IRE (Table 3, Figure 2).
3.8 | Other biomarkers and disease classification
A serum CRP concentration of 9.1 mg/L had a sensitivity of 72%
(95%CI: 47%–90%) and a specificity of 100% (95%CI: 74%–100%;
AUROC: 83%, 95%CI: 68%–98%) for the diagnosis of SRE/IRE versus
FRE/ARE, whereas a CCECAI score of 8 had a sensitivity of 68%
(95%CI: 44%–87%) and a specificity of 92% (95%CI: 64%–100%;
AUROC: 82%, 95%CI: 68%–96%) to distinguish these 2 groups of dogs.
A combination of at least 2 of these markers yielded an increased
sensitivity (about 80%), the highest sensitivity, and specificity being
reached for the combination of fecal calprotectin and serum CRP con-
centration (78% and 100%, respectively; Table 3).
3.9 | Fecal calprotectin concentrations and response
to treatment
Fecal calprotectin concentrations were also numerically higher in
dogs diagnosed with SRE/IRE that showed only PR or NR (median:
37.0 lg/g, IQR: 8.3–124.4 lg/g) compared to SRE/IRE dogs that
reached CR (median: 1.6 lg/g, IQR: 0.9–15.6 lg/g), but the difference
did not reach statistical significance (P5 .10) (Figure 3). A fecal calpro-
tectin concentration 15.2 lg/g was the only disease marker that, in
dogs with SRE/IRE could discriminate between dogs with PR/NR and
those dogs with CR, with a sensitivity of 80% (95%CI: 28%–100%) and
a specificity of 75% (95%CI: 43%–95%; AUROC: 77%, 95%CI:
53%–100%) (Table 3). Whether fecal calprotectin can also distinguish
TABLE 1 (Continued)
Group characteristic CIE (all) FRE/AREa SRE/IRE P valueb Pcorr
c
- Moderate (albumin 1.2-1.49 g/dL) 10 (8%) 1 (8%) 1 (5%)
- Severe (albumin <1.2 g/dL) 8 (6%) 0 (0%) 2 (10.5%)
Biomarkers of inflammation
Fecal calprotectin in lg/g, median (IQR) 1.6 (0.04–15.3) 1.4 (0.5–2.4) 2.0 (1.1–37.0) .10 .52
Fecal S100A12 in ng/g, median (IQR) 148 (22–899) 138 (35–248) 242 (71–1,709) .12 .58
Serum CRP in mg/L, median (IQR) 8.3 (1.2–25.8) 1.8 (0.2–4.5) 14.3 (5.4–37.8) .0028 .014
Serum calprotectin in lg/L, median (IQR) 6,389 (4,114–8,903) 5,083 (2,982–13,172) 9,320 (6,169–11,907) .45 1.00
Serum S100A12 in lg/L, median (IQR) 206 (144–328) 137 (77–252) 239 (155–412) .14 .71
Abbreviations: CCECAI, canine chronic enteropathy clinical activity index; FRE/ARE, food- or antibiotic-responsive enteropathy; SRE/IRE, steroid- or
immunosuppressant-responsive (or -refractory) enteropathy; IQR, interquartile range.
aIncluding 5 dogs with FRE or ARE that did not have gastrointestinal biopsies taken.
bSignificant difference between (or association with) ARE/FRE and SRE/IRE group (bold face values: P< .05).
cBonferroni corrected P value (n512, 7, 7, and 5).
dDocumented in n520 dogs.
eDocumented in n5126 dogs.
fDocumented in n5 125 dogs.
gDefined as 250 ng/L.
hDefined as 7.7 lg/L.
iDocumented in n5124 dogs
jDefined as 2.4 g/dL.
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TABLE 2 Correlation among clinical, laboratory, and histologic findings in dogs with CIE
Spearman q correlation coefficient (Pcorr)
a
Parameter
Correlated with Fecal canine calprotectin Fecal canine S100A12 Serum CRP CCECAI score
CCECAI score 0.27 (.039) 0.24 (.097) 0.42 (<.0006) –
Serum CRP concentration 0.16 (.71) 0.15 (.87) – 0.42 (<.0006)
Fecal canine S100A12 concentration 0.90 (<.0006) – 0.15 (.87) 0.24 (.097)
Serum calprotectin concentration 0.14 (1.00) 0.13 (1.00) 0.19 (.21) 0.20 (.71)
Serum S100A12 concentration 0.09 (1.00) 0.14 (1.00) 0.26 (.0018) 0.09 (1.00)
Histologic lesions (composite score)b 0.32 (1.00) 0.21 (1.00) 0.27 (1.00) 0.06 (1.00)
Morphologic criteriab 0.07 (1.00) 0.05 (1.00) 0.35 (.18) 0.16 (.85)
Inflammatory criteriab 0.52 (.036) 0.34 (.30) 0.10 (1.00) 20.03 (1.00)
Duodenum (composite score) 20.04 (1.00) 0.10 (1.00) 0.26 (.018) 0.07 (1.00)
Morphologic criteria (sum) 20.07 (1.00) 0.06 (1.00) 0.29 (.0048) 0.11 (.52)
 Villus stunting 20.08 (1.00) 20.03 (1.00) 0.23 (.033) 0.19 (.23)
 Epithelial injury 0.01 (1.00) 0.14 (.88) 0.16 (.48) 0.12 (1.00)
 Crypt distension 20.08 (1.00) 0.02 (1.00) 0.27 (.024) 0.11 (1.00)
 Lacteal dilatation 0.01 (1.00) 0.17 (.57) 0.18 (.32) 0.05 (1.00)
 Mucosal fibrosis 20.04 (1.00) 20.03 (1.00) 0.02 (1.00) 0.05 (1.00)
Inflammatory criteria (sum) 0.08 (.91) 0.10 (.67) 0.14 (.31) 0.02 (1.00)
 Intraepithelial lymphocytes 0.30 (.027) 0.30 (.017) 0.17 (.39) 0.05 (1.00)
 Lamina propria LPC 20.03 (1.00) 0.06 (1.00) 0.13 (.83) 0.03 (1.00)
 Lamina propria eosinophils 20.08 (1.00) 20.16 (.61) 20.12 (1.00) 20.18 (.30)
 Lamina propria neutrophils 0.17 (.57) 0.17 (.53) 0.24 (.061) 0.11 (1.00)
 Lamina propria MU 0.16 (.66) 0.15 (.82) 0.18 (.30) 0.24 (.0495)
Ileum (composite score) 0.25 (.59) 0.28 (.44) 0.13 (1.00) 0.04 (1.00)
Morphologic criteria (sum) 0.25 (.40) 0.17 (.77) 0.25 (.32) 0.07 (1.00)
 Villus stunting 0.07 (1.00) 20.05 (1.00) 0.32 (.32) 0.14 (1.00)
 Epithelial injury 0.21 (1.00) 0.19 (1.00) 0.24 (.89) 20.11 (1.00)
 Crypt distension 0.35 (.30) 0.32 (.48) 0.27 (.61) 20.24 (.87)
 Lacteal dilatation 20.07 (1.00) 20.05 (1.00) 0.01 (1.00) 0.34 (.22)
 Mucosal fibrosis N/A N/A N/A N/A
Inflammatory criteria (sum) 0.38 (.082) 0.33 (.16) 0.01 (1.00) 0.01 (1.00)
 Intraepithelial lymphocytes 0.29 (.64) 0.22 (1.00) 0.04 (1.00) 0.18 (1.00)
 Lamina propria LPC 0.41 (.14) 0.29 (.64) 0.12 (1.00) 0.02 (1.00)
 Lamina propria eosinophils 0.13 (1.00) 0.08 (1.00) 20.29 (.50) 20.26 (.68)
 Lamina propria neutrophils 0.12 (1.00) 0.23 (1.00) 0.01 (1.00) 20.07 (1.00)
 Lamina propria MU 0.24 (1.00) 0.25 (.95) 0.24 (.89) 0.05 (1.00)
Colon (composite score) 0.13 (1.00) 0.13 (1.00) 0.12 (1.00) 20.10 (1.00)
Morphologic criteria (sum) 0.03 (1.00) 0.05 (1.00) 0.18 (.48) 20.07 (1.00)
 Epithelial injury 0.05 (1.00) 0.11 (1.00) 0.09 (1.00) 0.06 (1.00)
 Goblet cell loss or hyperplasia 0.08 (1.00) 0.15 (1.00) 0.21 (.66) 20.11 (1.00)
 Crypt dilatation and distortion 0.04 (1.00) 0.05 (1.00) 0.20 (.73) 20.03 (1.00)
 Mucosal fibrosis and atrophy 20.05 (1.00) 20.19 (.96) 0.02 (1.00) 0.10 (1.00)
Inflammatory criteria (sum) 0.21 (.41) 0.21 (.38) 0.08 (1.00) 20.07 (1.00)
 Intraepithelial lymphocytes 0.19 (1.00) 0.16 (1.00) 0.17 (1.00) 20.13 (1.00)
 Lamina propria LPC 0.14 (1.00) 0.10 (1.00) 0.10 (1.00) 0.01 (1.00)
 Lamina propria eosinophils 0.06 (1.00) 0.02 (1.00) 20.31 (.18) 20.16 (1.00)
 Lamina propria neutrophils 20.03 (1.00) 0.01 (1.00) 0.17 (1.00) 0.05 (1.00)
 Lamina propria MU 0.06 (1.00) 0.13 (1.00) 0.11 (1.00) 0.10 (1.00)
Relationship between the 3-day mean fecal calprotectin concentrations and the clinical disease activity (CCECAI) score, concentrations of other inflam-
matory markers (serum CRP, serum and 3-day mean fecal S100A12, and serum calprotectin), and the severity of morphologic and inflammatory histo-
logic lesions in the duodenum, ileum, and colon in dogs with CIE (n5127).
Abbreviations: LPC, lymphocytes/plasma cells; MU, macrophages; N/A, not applicable; Pcorr, Bonferroni corrected P value (Pcorr5 P 3 n).
aOrange shaded cells: significant (bold face values indicate P< .05) only without Bonferroni correction; blue shaded cells: significance (bold face values
indicate P< .05) remaining after Bonferroni correction (n5 2, 3, 4, or 5).
bCalculated only when duodenum, ileum, and colon were sampled and evaluated.
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SRE/IRE dogs with PR from those with NR could not be tested because
of the small number of individuals in these groups of dogs.
Fecal calprotectin concentrations decreased significantly from
before treatment initiation (median: 1.5 lg/g, IQR: 0.7–29.0 lg/g) to
after treatment (median: 0.04 lg/g, IQR: 0.04-0.2 lg/g; P5 .0039) in
SRE/IRE dogs with CR, but the change in fecal calprotectin concentra-
tions could not be evaluated in those SRE/IRE dogs with PR/NR
because of the small sample size of these subgroups.
4 | DISCUSSION
The aim of our study was to evaluate the potential clinical utility of
measuring fecal canine calprotectin concentration as a noninvasive
marker for the diagnosis and monitoring of dogs with CIE. Fecal cal-
protectin concentrations correlated with the severity of clinical signs
and with fecal S100A12 but not with serum CRP concentrations.
Fecal calprotectin was also moderately correlated with the severity of
intestinal (duodenal) inflammation. Dogs with SRE/IRE, and particu-
larly dogs with PR/NR, had higher fecal calprotectin concentrations
than dogs diagnosed with FRE or ARE. Age, sex, and breed distribu-
tion in our study were found to be similar to those reported by
others.7,10,21,32
Serum CRP concentration, together with fecal calprotectin concen-
tration, belongs to the most widely used markers in human inflamma-
tory bowel disease (IBD).33–35 Serum CRP concentrations were also
evaluated in our study and were found to not correlate with fecal cal-
protectin concentrations. This is consistent with some studies in human
IBD patients showing no correlation between both biomarkers in
patients with ulcerative colitis (UC)36 but contrasts the findings of
others where CRP was moderately correlated with fecal calprotectin in
patients with Crohn’s disease (CD)33,35–37 or UC,35,37 and it also agrees
with the lack of a correlation between serum calprotectin and CRP in
dogs with idiopathic IBD.11 These findings suggest that the intestinal
inflammation in dogs with CIE is not related to the systemic inflamma-
tory response. However, a high-sensitivity CRP test, which was shown
to be superior to standard CRP assays for the detection and differentia-
tion of low serum concentrations of CRP (<5 mg/L) in humans,38 is
currently not available for use in dogs. Also, a high biological variability
of serum CRP concentrations within individual dogs39 and nonspecific
increases in serum CRP concentration in response to other inflamma-
tory conditions (eg, pancreatitis)40 can limit the clinical usefulness of
this biomarker for diagnosing or monitoring CIE in dogs. Being a bio-
marker that is measured in fecal samples, it is reasonable to assume
that fecal calprotectin is specific for the GI tract.19 Calprotectin has
also been shown to be stable in naturally passed fecal samples for at
FIGURE 2 Fecal calprotectin concentrations, serum CRP concentrations, and CCECAI scores in relation to disease classification in dogs
with CIE. (A) Fecal calprotectin concentrations were numerically higher in dogs with SRE/IRE (n519) compared to dogs with FRE/ARE
(n513), but the difference was not significant (P5 .10). (B) Serum CRP concentrations and (C) CCECAI scores were significantly higher in
dogs with SRE/IRE than in dogs with FRE/ARE (P5 .0028 and .0025, respectively). the optimum cut-off values for sensitivity and specificity
calculation determined by ROC curve analyses were (D) a fecal calprotectin concentration 15.2 lg/g, (E) a serum CRP concentration
9.1 mg/L, and (F) a CCECAI score 8
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least 7 days,41 and thus can easily be measured in samples collected in
the dog’s home environment by the owner.
The canine IBD activity index (CIBDAI)6 or CCECAI7 scoring sys-
tems are often used for semi-objective assessment of clinical disease
activity and response to treatment. Similar to previous studies finding
lower clinical disease scores in dogs with FRE compared to dogs with
SRE/IRE,2,32 CCECAI scores in dogs with FRE/ARE were lower com-
pared to dogs diagnosed with SRE/IRE in our study. The relationship
between fecal calprotectin concentrations and clinical disease activity
(CCECAI) scores is also consistent with our previous results in dogs
with chronic diarrhea where higher CCECAI scores were associated
with higher fecal calprotectin concentrations and a fecal calprotectin
concentration 48.9 lg/g predicted severe clinical signs (CCECAI
scores 12) with moderate sensitivity and high specificity.20 Our
results also agree with studies in children and human adults with
IBD,33,35,42–46 where the correlation between fecal calprotectin and
clinical disease activity indices was shown to be generally weaker in
dogs with CD33,35,45 than in those with UC.42–45
The minimum amount of time that clinical signs had to be present
was 2–3 weeks, which is slightly shorter than the time reported in the
2010 consensus statement.3 The inclusion of dogs in the study when
GI signs were noticeable to the owner for at least 2 weeks (n54 dogs,
3%) was considered an appropriate criterion for dogs with severe clini-
cal signs or marked clinicopathologic findings (ie, hypoalbuminemia/
panhypoproteinemia and hypocobalaminemia, both of which were
shown to be negative prognostic factors7) indicating intestinal protein
loss. All 4 dogs had moderate to marked lesions on histopathologic
examination of intestinal (duodenal) biopsies in addition to hypoalbumi-
nemia and hypofolatemia, hypocobalaminemia, or both.
Histopathologic evaluation of GI tissue biopsies, in combination
with clinical signs and systematic therapeutic trials, is currently the gold
standard for the diagnosis of CIE. The severity of clinical signs (based
on CIBDAI6 or CCECAI scores7) has been shown to not reflect the
severity of histologic lesions,7,15 which is also supported by the findings
of the present study. Correlation of fecal calprotectin concentrations
with histologic inflammatory lesions in the small intestine and the
extent of intestinal inflammation (ie, cumulative lesion score) also
agrees with the results of studies in children and adult human patients
with IBD, where fecal calprotectin concentrations correlated with the
severity of histologic inflammation and cut-off concentrations between
100 and 170 lg/g had strong predictive value for histologic remis-
sion.44,45,47,48 These findings suggest that fecal calprotectin testing
could be a good surrogate marker to evaluate disease severity.
Fecal calprotectin concentrations were correlated with histologic
inflammatory lesions, particularly lamina propria lymphocytes in the
ileum, but not with the number of intestinal lamina propria neutrophils
and macrophage(s) (MU) (especially in the colon). The latter was an
unexpected finding as calprotectin is predominantly expressed by acti-
vated neutrophils and MU19,49 and because calprotectin correlates
with the number of infiltrating neutrophils in human IBD.50 A possible
explanation could be that, while the inflammatory infiltrate in canine
CIE is primarily lymphoplasmacytic with an eosinophilic component in
some cases, neutrophils and eosinophils can be very difficult to identify
depending on tissue processing and staining.51,52 In line with this, histo-
pathologic changes (primarily the number of T lymphocytes in the lam-
ina propria) poorly correlate with clinical disease or response to
treatment.53–55 An alternative explanation for this finding could be that
calprotectin expression does not merely reflect the number of intestinal
lamina propria neutrophils and MU, but rather reflects the activity of
these cells. In human IBD, it is believed that activated MU contribute
to the production of inflammatory cytokines that lead to altered che-
motactic signals and an increased recruitment of lymphocytes.56 In
dogs with CIE, only few cytokines have been evaluated based on
mRNA analysis and the results have been inconsistent.57,58 However,
TABLE 3 Diagnostic accuracy of the biomarkers in dogs with CIE
Parameter
Sensitivity
(%)
Specificity
(%)
OR
(95%CI) P valuea Pcorr
b
Classification of CIE—diagnosis of SRE/IRE (n519) versus FRE/ARE (n5 13)
Fecal calprotectin 15.2 lg/g 37 100 7.5 (1.0–90.0)c .059 .18
Serum CRP 9.1 mg/L 72 100 22.3 (2.9–253.4)c .0006 .0018
CCECAI score 8 68 92 26 (3.3–295.2) .0009 .0027
Fecal calprotectin 15.2 lg/g or serum CRP 9.1 mg/L 78 100 48.8 (5.5–542.9)c <.0001 <.0003
Fecal calprotectin 15.2 lg/g or CCECAI score 8 79 92 45.0 (5.0–503.9) <.0001 <.0003
Serum CRP 9.1 mg/L or CCECAI score 8 79 92 58.7 (5.7–656.0) <.0001 <.0003
Fecal calprotectin 15.2 lg/g or CCECAI score 8 or serum
CRP 9.1 mg/L
88 92 93.5 (7.4–1,035.0) <.0001 <.0001
Response to treatment—PR/NR (n55) versus CR (n5 12) (dogs with SRE/IRE only)
Fecal calprotectin 15.2 lg/g 80 75 20.0 (1.3–261.0) .028 .08
Serum CRP 12.9 mg/L 60 36 0.9 (0.1–6.5) 1.00 ns
CCECAI score 12 40 100 13 (1.3–177.8)c .074 .22
Performance and cut–off levels for fecal calprotectin, serum CRP, and the clinical activity index (CCECAI) to predict SRE/IRE versus FRE/ARE in dogs
with CIE (n5 32) and to predict PR/NR versus CR in dogs with SRE/IRE (n519).
aFisher’s exact test.
bBonferroni corrected P value; blue shaded cells: best performing biomarker (or combination of biomarkers) to distinguish the different groups of dogs;
values in bold face indicate significance at P< .05; ns: not significant (P>1.0000).
cEstimated using the probabilistic solution to dealing with zero counts.29
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numbers of cells staining positive for leukocyte protein-1 (ie, MU and
neutrophils)59 and activated MU (determined by staining for activated
nuclear factor-kappa B, NF-jB60) in the lamina propria were shown to
be increased in canine IBD. Also, mucosal Toll-like receptor (TLR)2- and
TLR4-mRNA expression was upregulated in canine IBD.5,61,62 Interest-
ingly, calprotectin is an endogenous ligand for TLR4 and NF-jB is
involved in the expression of proinflammatory mediators downstream
of TLR4.49 Calprotectin has also been shown to be induced in epithelial
cells in humans49 and whether this is also true in dogs warrants further
study.
The heterogenous response to treatment in dogs with CIE is the
basis for classification of the disease into FRE, ARE, and SRE/IRE,
whose features are often indistinguishable on endoscopy or histopa-
thology.1,2,32 A noninvasive test that could identify dogs likely to fail
treatment trials with antibiotics, elimination diets, or both before a
treatment decision is made, would be a useful tool in clinical practice.
Fecal calprotectin concentrations were numerically higher in dogs with
SRE/IRE compared to dogs with FRE or ARE in our study, but signifi-
cance was not reached likely because the comparison was underpow-
ered. A cut-off fecal calprotectin concentration of 15.2 lg/g was able
to discriminate between both groups with moderate sensitivity (37%)
and high specificity (100%). Diagnostic accuracy to detect dogs with
SRE/IRE was improved when fecal calprotectin was used in combina-
tion with serum CRP (cut-off concentration: 9.1 mg/L), the CCECAI
score (cut-off score: 8), or both. These findings are in line with our
previous investigations showing calprotectin concentrations to be
increased in serum from dogs with SRE/IRE compared to healthy
dogs11 and also in pretreatment fecal samples from dogs with SRE/IRE
compared to healthy controls.21 Measuring higher fecal calprotectin
concentrations in dogs with SRE/IRE is also consistent with studies in
human medicine showing that increased fecal calprotectin concentra-
tions can identify dogs with active IBD from either non-IBD controls
or IBD dogs in remission,35,44,45,63 and is also similar to the results
reported for fecal S100A12 concentrations in dogs.16 The current
study suggests that a pretreatment fecal calprotectin concentration of
15.2 lg/g might signal the need for more aggressive (ie, immunosup-
pressive, anti-inflammatory, or both) treatment in CIE dogs, but a com-
bination with serum CRP, CCECAI score, or both yielded a higher
diagnostic accuracy.
Disease classification in dogs with CIE is based on the response to
treatment,1,2,7,32 and the best time to perform more invasive diagnos-
tics (ie, endoscopy with collection of GI tissue biopsies) is often
debated in clinical practice.64 This is also reflected in the dog popula-
tion of our study, where 8 dogs with FRE/ARE (62%) had GI tissue
biopsies taken and 5 dogs included in the FRE/ARE group (38%) did
not have biopsies taken. While intestinal inflammation was not docu-
mented in these 5 dogs, the mild clinical signs (CCECAI scores of 2, 3,
3, 5, and 6) and relatively long follow-up time (6, 13, 24, 52, and 169
weeks) render FRE/ARE the most likely diagnosis. However, another
intestinal disease process cannot be entirely excluded in these dogs.
FIGURE 3 Fecal calprotectin concentrations, serum CRP concentrations, and CCECAI scores in relation to the response to treatment in
SRE/IRE dogs. (A) Fecal calprotectin concentrations were numerically higher in SRE/IRE dogs with PR/NR (n59) compared to those dogs
with CR (n511), but the difference was not significant (P5 .10). Between SRE/IRE dogs with PR/NR and dogs with CR there was no
significant difference in (B) serum CRP concentrations (P51.00) and (C) CCECAI scores (P5 .49). The optimum cut-off values for sensitivity
and specificity calculation determined by ROC curve analyses were (D) a fecal calprotectin concentration 15.2 lg/g, (E) a serum CRP con-
centration 12.9 mg/L, and (F) a CCECAI score 12
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Fecal calprotectin concentrations were numerically higher in SRE/
IRE dogs with PR/NR compared to those dogs with CR, but significance
was not reached likely because of the low statistical power. Higher pre-
treatment fecal calprotectin concentrations in SRE/IRE dogs with only
partial or no response to treatment (PR/NR) is consistent with the
results of studies in children and human adults with IBD showing lower
fecal calprotectin concentrations to predict clinical remission44 or to
predict sustained clinical remission over 1 year.65,66 This finding also
agrees with the results for fecal S100A12 in dogs with CIE where fecal
S100A12 concentrations 2,700 ng/g identified dogs with IBD that
were refractory to anti-inflammatory/immunosuppressive treatment.16
In the present study, the diagnostic accuracy of fecal calprotectin to
predict PR/NR was also superior to that of serum CRP and the CCECAI
score, and the lack of a relationship between clinical disease severity
and outcome contrasts the findings of other studies that showed the
individual outcome to be significantly associated with higher clinical
disease activity scores.7,32 Thus, fecal calprotectin could be a clinically
useful surrogate marker for the diagnosis and management of canine
CIE. However, further research is needed to evaluate the time course
of changes in fecal calprotectin concentrations in dogs with CIE, partic-
ularly in dogs with SRE/IRE before, during, and after clinical flares. Fur-
ther studies are also needed to assess the utility of fecal calprotectin as
a surrogate marker to guide diagnostic and clinical decision-making in
dogs with CIE.
The present study aimed to determine the value of measuring fecal
calprotectin concentrations in dogs with intestinal inflammatory lesions,
and dogs diagnosed with GI cancer were excluded from the study.
However, increased fecal calprotectin concentrations have also been
detected in people with GI malignancies,67,68 and the possibility that
fecal calprotectin concentrations are also altered in dogs with alimen-
tary neoplasms cannot be excluded. Thus, further evaluation of fecal
calprotectin concentrations in canine GI neoplasia is warranted. Until
more data is available, fecal calprotectin might be seen as a good surro-
gate biomarker of GI inflammation but will not be a replacement for
biopsy or other clinicopathologic tests.
Our study had some limitations. First, the clinical response to treat-
ment was used as the primary endpoint of the study, and the possibility
of a correlation with mucosal healing (deep remission) was not eval-
uated. Second, single spot fecal samples were used to measure fecal
calprotectin concentrations, but the biological variation of fecal calpro-
tectin concentrations has only been estimated in a small number of
dogs with CIE.24 Third, long-term outcome (ie, a follow-up period of
>12 months) was not evaluated in the majority of dogs in our study.
Fourth, the small sample size in subgroup analyses (ie, disease classifi-
cation and response to treatment) has the potential for a type I or type
II error. Fifth, several different clinicians were involved in evaluating
the CCECAI score, which may add some variability. However, the CCE-
CAI scoring system is 1 of the 2 standardized semi-objective methods
for evaluation of clinical disease severity in dogs with chronic enteropa-
thies, and it has been used in a number of investigations. Further, histo-
pathologic evaluation of GI tissue biopsies was performed by 1 of 7
different pathologists (though with a special expertise in GI pathology)
and interobserver variability exists even with the use of standardized
criteria.69 Further, given the multicenter nature of our clinical observa-
tional study, it was not feasible to standardize treatment and follow-up
for all dogs, and some flexibility in the diagnostic evaluation was
needed to accommodate dogs with severe clinical signs, marked clinico-
pathological abnormalities (eg, severe hypoalbuminemia), or both. Also,
choices and doses of immunosuppressives were not standardized in
our study. Lastly, the possibility of missing a diffusely infiltrating neo-
plasm (ie, alimentary lymphoma) in dogs diagnosed with CIE cannot be
excluded as biopsies were not available from all section of the GI tract
in all dogs and because endoscopy does not allow evaluation of the
entire small intestine.
5 | CONCLUSIONS
We conclude that fecal calprotectin appears to be a potentially useful
variable as a surrogate to assess the severity of GI inflammation in
dogs with CIE. Before treatment, fecal calprotectin concentrations had
a good ability to distinguish between dogs with SRE/IRE and dogs with
FRE or ARE, but CCECAI scores and serum CRP concentrations as a
single variable outperformed the fecal calprotectin test. Assessing fecal
calprotectin in combination with serum CRP, the CCECAI score, or
both increased the ability to differentiate these conditions. Lower pre-
treatment concentrations of fecal calprotectin in dogs that have failed
dietary and antibiotic treatment trials could indicate a higher likelihood
of a response to anti-inflammatory/immunosuppressive treatment.
Thus, a prospective evaluation of the clinical utility of fecal calprotectin
in determining the disease classification and predicting the response to
treatment in CIE dogs undergoing a standardized diagnostic and treat-
ment regimen is warranted.
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